Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | April 2013 |
| Contact: | Diane Reyes, RN |
| Email: | dreyes1@jhmi.edu |
| Phone: | 410-614-4212 |
Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer
The purpose of this study is to determine the whether Lipiodol can be used as an imaging
biomarker, predicting tumor response to therapy in patients with primary and metastatic
liver cancer. Lipiodol-based transarterial chemoembolization (TACE) has been an accepted
standard of care procedure for unresectable liver lesions for several decades. Lipiodol is
used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE
procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via
the hepatic artery, causing necrosis of the targeted tumor(s). Response to therapy will be
evaluated every 1, 3 and 6 months by clinic visits, MRI/ CT scans and blood tests (to
include assessment of liver function and tumor markers). After the 6th month, patients will
be followed every 2-3 months for a period of up to 4 years.
biomarker, predicting tumor response to therapy in patients with primary and metastatic
liver cancer. Lipiodol-based transarterial chemoembolization (TACE) has been an accepted
standard of care procedure for unresectable liver lesions for several decades. Lipiodol is
used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE
procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via
the hepatic artery, causing necrosis of the targeted tumor(s). Response to therapy will be
evaluated every 1, 3 and 6 months by clinic visits, MRI/ CT scans and blood tests (to
include assessment of liver function and tumor markers). After the 6th month, patients will
be followed every 2-3 months for a period of up to 4 years.
Inclusion Criteria:
1. 18 years of age or older.
2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
3. Childs class of A or B (up to 9).
4. Hepatocellular carcinoma (HCC) is unresectable with liver-predominant disease or
subject has HCC and refused surgery or subject is diagnosed hepatic metastases from
any solid tumor. (Multifocal HCC is acceptable, no diffuse HCC).
5. Subject is voluntarily participating in the study and has signed the informed
consent.
Exclusion Criteria:
1. Contraindications to doxorubicin, cisplatin, or mytomycin-c administration (or
specific mixture of chemotherapy drugs to be used).
2. Evidence of severe or uncontrolled systemic diseases.
3. Congestive cardiac failure >NYHA class 2 MI within 6 months, active coronary artery
disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta
blockers or digoxin, unstable angina, or laboratory finding that in the view of the
investigator makes it undesirable for the patient to participate in the trial.
4. Known allergy to Lipiodol (Ethiodol), poppy seed oil, or iodinated contrast agents
(that cannot be adequately mitigated with pre-procedure medication).
5. Main portal vein thrombosis is excluded; segmental or branch portal vein thrombosis
is acceptable.
6. Subject is breastfeeding.
7. Subject is pregnant
We found this trial at
1
site
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
